BLUEPRINT MEDICINES CORP (BPMC) Stock Price, Forecast & Analysis
NASDAQ:BPMC • US09627Y1091
BPMC Key Statistics, Chart & Performance
The current stock price of BPMC is 129.46 USD. In the past month the price increased by 0.96%. In the past year, price increased by 12.6%.
BPMC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BPMC. When comparing the yearly performance of all stocks, BPMC is one of the better performing stocks in the market, outperforming 87.01% of all stocks.
BPMC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BPMC. BPMC may be in some trouble as it scores bad on both profitability and health.
BPMC Financial Highlights
Over the last trailing twelve months BPMC reported a non-GAAP Earnings per Share(EPS) of -3.22. The EPS increased by 57.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.03% | ||
| ROE | -45.52% | ||
| Debt/Equity | 1.01 |
BPMC Forecast & Estimates
25 analysts have analysed BPMC and the average price target is 132.96 USD. This implies a price increase of 2.71% is expected in the next year compared to the current price of 129.46.
For the next year, analysts expect an EPS growth of 76.13% and a revenue growth 41.72% for BPMC
BPMC Ownership
BPMC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BPMC
Company Profile
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Company Info
BLUEPRINT MEDICINES CORP
45 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jeffrey W. Albers
Employees: 649
Phone: 16173747580
BLUEPRINT MEDICINES CORP / BPMC FAQ
Can you describe the business of BLUEPRINT MEDICINES CORP?
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
What is the current price of BPMC stock?
The current stock price of BPMC is 129.46 USD. The price increased by 0.14% in the last trading session.
What is the dividend status of BLUEPRINT MEDICINES CORP?
BPMC does not pay a dividend.
How is the ChartMill rating for BLUEPRINT MEDICINES CORP?
BPMC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is BLUEPRINT MEDICINES CORP (BPMC) stock traded?
BPMC stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for BLUEPRINT MEDICINES CORP?
The Revenue of BLUEPRINT MEDICINES CORP (BPMC) is expected to grow by 41.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for BLUEPRINT MEDICINES CORP?
BLUEPRINT MEDICINES CORP (BPMC) has a market capitalization of 8.37B USD. This makes BPMC a Mid Cap stock.